Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma

PURPOSE: Complement C1q, the initiating molecule of the classical complement cascade, is involved in synapse elimination and neuronal loss in neurodegenerative diseases including glaucoma. Here we report an evaluation of the safety, tolerability, and ocular pharmacokinetics (PK) and pharmacodynamics...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yang, Wirta, David, Murahashi, Wendy, Mathur, Vidhu, Sankaranarayanan, Sethu, Taylor, Lori K., Yednock, Ted, Fong, Donald S., Goldberg, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130689/
https://www.ncbi.nlm.nih.gov/pubmed/37124168
http://dx.doi.org/10.1016/j.xops.2023.100290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130689/
https://www.ncbi.nlm.nih.gov/pubmed/37124168
http://dx.doi.org/10.1016/j.xops.2023.100290

Ejemplares similares